{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:22:37Z","timestamp":1747207357493,"version":"3.40.5"},"reference-count":69,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CAD"],"published-print":{"date-parts":[[2020,9,3]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Ixora coccinea is a tropical ornamental shrub employed in ethnomedicine for the treatment of a number of diseases none of which include the Human Immunodeficiency Virus (HIV) infection. Ixoratannin A-2, one of the constituents, was previously identified via virtual-screening and experimentally confirmed to possess significant anti-HIV-1 activity in an in vitro CD4+ replication assay. This activity was observed to be significantly reduced in degree in viruses lacking the protein Vpu. This suggests the involvement of Vpu as well as other extra-Vpu macromolecules in its antiviral activity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>In the present computational search for the identity of the other macromolecules that could possibly explain the observed activity, a panel of fourteen established HIV-1 macromolecular targets was assembled against which ixoratannin A-2 and other major phytoconstituents of I. coccinea were virtually screened.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>Structural analyses of the computed ligand-bound complexes, as well as the careful investigation of the thermodynamic attributes of the predicted binding, revealed subtle selectivity patterns at the atomistic level that suggest the likely involvement of multiple macromolecular processes. Some of the binding interactions were found to be thermodynamically favourable, including the multidrug-resistant HIV protease enzyme, CXCR4 and the human elongin C protein all of which formed reasonably strong interactions with ixoratannin A-2 and other constituents of I. coccinea.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion:<\/jats:title><jats:p>Ixoratannin A-2\u2019s ability to favourably interact with multiple HIV-1 and human targets could explain its observed extra-Vpu antiviral activity. This, however, does not imply uncontrolled binding with all available targets; on the other hand, molecular size of ixoratannin A-2 and combination of functional groups confer on it a decent level of selectivity against many of the investigated HIV\/AIDS targets.<\/jats:p><\/jats:sec>","DOI":"10.2174\/1573409915666190702111023","type":"journal-article","created":{"date-parts":[[2019,7,3]],"date-time":"2019-07-03T10:45:26Z","timestamp":1562150726000},"page":"376-388","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Computational Prospecting for the Pharmacological Mechanism of Activity: HIV-1 Inhibition by Ixoratannin A-2"],"prefix":"10.2174","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9412-6776","authenticated-orcid":true,"given":"Olujide O.","family":"Olubiyi","sequence":"first","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8154-7432","authenticated-orcid":true,"given":"Thomas O.","family":"Idowu","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9356-497X","authenticated-orcid":true,"given":"Abiodun O.","family":"Ogundaini","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6521-1536","authenticated-orcid":true,"given":"Goodness","family":"Orhuah","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Obafemi Awolowo University, Ile-Ife, Nigeria"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","first-page":"67","volume":"10","author":"Shafer R.W.","year":"2008","unstructured":"Shafer R.W.; Schapiro J.M.; HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. AIDS Rev 2008,10(2),67-84","journal-title":"AIDS Rev"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"123","DOI":"10.21010\/ajtcam.v13i4.17","volume":"13","author":"Mugomeri E.","year":"2016","unstructured":"Mugomeri E.; Chatanga P.; Chakane N.; Medicinal herbs used by HIV-positive people in Lesotho. Afr J Tradit Complement Altern Med 2016,13(4),123-131","journal-title":"Afr J Tradit Complement Altern Med"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/S0378-8741(02)00009-0","volume":"80","author":"Vermani K.","year":"2002","unstructured":"Vermani K.; Garg S.; Herbal medicines for sexually transmitted diseases and AIDS. J Ethnopharmacol 2002,80(1),49-66","journal-title":"J Ethnopharmacol"},{"key":"ref=4","first-page":"74","volume":"1","author":"Chinsembu K.","year":"2010","unstructured":"Chinsembu K.; Hedimbi M.; Ethnomedicinal plants and other natural products with anti-HIV active compounds and their putative modes of action. Int J Biotechnol Mol Biol Res 2010,1,74-91","journal-title":"Int J Biotechnol Mol Biol Res"},{"key":"ref=5","first-page":"613","volume":"67","year":"1989","unstructured":"In vitro screening of traditional medicines for anti-HIV Activity: memorandum from a WHO meeting. Bull World Health Organ World Health Organization1989,67,613-618","journal-title":"Bull World Health Organ"},{"year":"1989","key":"ref=6","unstructured":"Report of a WHO informal consultation on traditional medicine and AIDS: In vitro screening for anti- HIV activity, Geneva, 6-8 February World Health Organization1989"},{"year":"2002","key":"ref=7","unstructured":"WHO traditional medicine strategy 2002-2005 World Health Organization2002"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/1099-1573(200102)15:1<62::AIDPTR956>3.0.CO;2-X","volume":"15","author":"Asres K.","year":"2001","unstructured":"Asres K.; Bucar F.; Kartnig T.; Witvrouw M.; Pannecouque C.; De Clercq E.; Antiviral activity against human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) of ethnobotanically selected Ethiopian medicinal plants. Phytother Res 2001,15(1),62-69","journal-title":"Phytother Res"},{"key":"ref=9","first-page":"69","volume":"109","author":"Fabricant D.S.","year":"2001","unstructured":"Fabricant D.S.; Farnsworth N.R.; The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 2001,109(Suppl. 1),69-75","journal-title":"Environ Health Perspect"},{"key":"ref=10","first-page":"42","author":"Farnsworth N.R.","year":"2007","unstructured":"Farnsworth N.R.; Ethnopharmacology and drug development, in Ciba Foundation Symposium 185 - Ethnobotany and the search for new drugs Eds Chadwick, D.J. Marsh, J. Hoboken2007,42-59"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"2871","DOI":"10.3390\/md8122871","volume":"8","author":"Vo T.S.","year":"2010","unstructured":"Vo T.S.; Kim S.K.; Potential anti-HIV agents from marine resources: an overview. Mar Drugs 2010,8(12),2871-2892","journal-title":"Mar Drugs"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"1331","DOI":"10.2174\/138955710793564133","volume":"10","author":"Jiang Y.","year":"2010","unstructured":"Jiang Y.; Ng T.B.; Wang C.R.; Zhang D.; Cheng Z.H.; Liu Z.K.; Qiao W.T.; Geng Y.Q.; Li N.; Liu F.; Inhibitors from natural products to HIV-1 reverse transcriptase, protease and integrase. Mini Rev Med Chem 2010,10(14),1331-1344","journal-title":"Mini Rev Med Chem"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"531","DOI":"10.2174\/157016210793499204","volume":"8","author":"Filho J.R.","year":"2010","unstructured":"Filho J.R.; de Sousa Falc\u00e3o H.; Batista L.M.; Filho J.M.; Piuvezam M.R.; Effects of plant extracts on HIV-1 protease. Curr HIV Res 2010,8(7),531-544","journal-title":"Curr HIV Res"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1472-6882-9-29","volume":"9","author":"Park I.W.","year":"2009","unstructured":"Park I.W.; Han C.; Song X.; Green L.A.; Wang T.; Liu Y.; Cen C.; Song X.; Yang B.; Chen G.; He J.J.; Inhibition of HIV-1 entry by extracts derived from traditional Chinese medicinal herbal plants. BMC Complement Altern Med 2009,9,29","journal-title":"BMC Complement Altern Med"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"1781","DOI":"10.1039\/c0np00025f","volume":"27","author":"Singh I.P.","year":"2010","unstructured":"Singh I.P.; Bodiwala H.S.; Recent advances in anti-HIV natural products. Nat Prod Rep 2010,27(12),1781-1800","journal-title":"Nat Prod Rep"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/ptr.1629","volume":"19","author":"Asres K.","year":"2005","unstructured":"Asres K.; Seyoum A.; Veeresham C.; Bucar F.; Gibbons S.; Naturally derived anti-HIV agents. Phytother Res 2005,19(7),557-581","journal-title":"Phytother Res"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"2084","DOI":"10.1016\/j.bmc.2011.01.024","volume":"19","author":"Balestrieri E.","year":"2011","unstructured":"Balestrieri E.; Pizzimenti F.; Ferlazzo A.; Giofr\u00e8 S.V.; Iannazzo D.; Piperno A.; Romeo R.; Chiacchio M.A.; Mastino A.; Macchi B.; Antiviral activity of seed extract from Citrus bergamia towards human retroviruses. Bioorg Med Chem 2011,19(6),2084-2089","journal-title":"Bioorg Med Chem"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1021\/jm950922q","volume":"39","author":"Kashiwada Y.","year":"1996","unstructured":"Kashiwada Y.; Hashimoto F.; Cosentino L.M.; Chen C.H.; Garrett P.E.; Lee K.H.; Betulinic acid and dihydrobetulinic acid derivatives as potent anti-HIV agents. J Med Chem 1996,39(5),1016-1017","journal-title":"J Med Chem"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1021\/jm900136j","volume":"52","author":"Qian K.","year":"2009","unstructured":"Qian K.; Yu D.; Chen C.H.; Huang L.; Morris-Natschke S.L.; Nitz T.J.; Salzwedel K.; Reddick M.; Allaway G.P.; Lee K.H.; Anti-AIDS agents. 78. Design, synthesis, metabolic stability assessment, and antiviral evaluation of novel betulinic acid derivatives as potent anti-human immunodeficiency virus (HIV) agents. J Med Chem 2009,52(10),3248-3258","journal-title":"J Med Chem"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1128\/AAC.45.4.1225-1230.2001","volume":"45","author":"Kanamoto T.","year":"2001","unstructured":"Kanamoto T.; Kashiwada Y.; Kanbara K.; Gotoh K.; Yoshimori M.; Goto T.; Sano K.; Nakashima H.; Anti-human immunodeficiency virus activity of YK-FH312 (a betulinic acid derivative), a novel compound blocking viral maturation. Antimicrob Agents Chemother 2001,45(4),1225-1230","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"3574","DOI":"10.1128\/AAC.00152-07","volume":"51","author":"Smith P.F.","year":"2007","unstructured":"Smith P.F.; Ogundele A.; Forrest A.; Wilton J.; Salzwedel K.; Doto J.; Allaway G.P.; Martin D.E.; Phase I and II study of the safety, virologic effect, and pharmacokinetics\/pharmacodynamics of single-dose 3-o-(3\u2032,3\u2032-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother 2007,51(10),3574-3581","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"4271","DOI":"10.1021\/jm020069c","volume":"45","author":"Sun I.C.","year":"2002","unstructured":"Sun I.C.; Chen C.H.; Kashiwada Y.; Wu J.H.; Wang H.K.; Lee K.H.; Anti-AIDS agents 49. Synthesis, anti-HIV, and anti-fusion activities of IC9564 analogues based on betulinic acid. J Med Chem 2002,45(19),4271-4275","journal-title":"J Med Chem"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.jep.2005.11.008","volume":"105","author":"Wang R.R.","year":"2006","unstructured":"Wang R.R.; Gu Q.; Yang L.M.; Chen J.J.; Li S.Y.; Zheng Y.T.; Anti-HIV-1 activities of extracts from the medicinal plant Rhus chinensis. J Ethnopharmacol 2006,105(1-2),269-273","journal-title":"J Ethnopharmacol"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1128\/AAC.47.9.2810-2816.2003","volume":"47","author":"Chen X.","year":"2003","unstructured":"Chen X.; Yang L.; Zhang N.; Turpin J.A.; Buckheit R.W.; Osterling C.; Oppenheim J.J.; Howard O.M.; Shikonin, a component of chinese herbal medicine, inhibits chemokine receptor function and suppresses human immunodeficiency virus type 1. Antimicrob Agents Chemother 2003,47(9),2810-2816","journal-title":"Antimicrob Agents Chemother"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/1472-6882-11-112","volume":"11","author":"Han H.","year":"2011","unstructured":"Han H.; He W.; Wang W.; Gao B.; Inhibitory effect of aqueous Dandelion extract on HIV-1 replication and reverse transcriptase activity. BMC Complement Altern Med 2011,11,112","journal-title":"BMC Complement Altern Med"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1055\/s-2006-957384","volume":"64","author":"Vlietinck A.J.","year":"1998","unstructured":"Vlietinck A.J.; De Bruyne T.; Apers S.; Pieters L.A.; Plant-derived leading compounds for chemotherapy of human immunodeficiency virus (HIV) infection. Planta Med 1998,64(2),97-109","journal-title":"Planta Med"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1055\/s-2002-20058","volume":"68","author":"Dharmaratne H.R.W.","year":"2002","unstructured":"Dharmaratne H.R.W.; Tan G.T.; Marasinghe G.P.K.; Pezzuto J.M.; Inhibition of HIV-1 reverse transcriptase and HIV-1 replication by Calophyllum coumarins and xanthones. Planta Med 2002,68(1),86-87","journal-title":"Planta Med"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1016\/S0968-0896(00)82054-4","volume":"2","author":"Lee T.T-Y.","year":"1994","unstructured":"Lee T.T-Y.; Kashiwada Y.; Huang L.; Snider J.; Cosentino M.; Lee K-H.; Suksdorfin: an anti-HIV principle from Lomatium suksdorfii, its structure-activity correlation with related coumarins, and synergistic effects with anti-AIDS nucleosides. Bioorg Med Chem 1994,2(10),1051-1056","journal-title":"Bioorg Med Chem"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/med.10034","volume":"23","author":"Yu D.","year":"2003","unstructured":"Yu D.; Suzuki M.; Xie L.; Morris-Natschke S.L.; Lee K-H.; Recent progress in the development of coumarin derivatives as potent anti-HIV agents. Med Res Rev 2003,23(3),322-345","journal-title":"Med Res Rev"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/S0031-9422(99)00554-3","volume":"53","author":"Zhou P.","year":"2000","unstructured":"Zhou P.; Takaishi Y.; Duan H.; Chen B.; Honda G.; Itoh M.; Takeda Y.; Kodzhimatov O.K.; Lee K.H.; Coumarins and bicoumarin from Ferula sumbul: anti-HIV activity and inhibition of cytokine release. Phytochemistry 2000,53(6),689-697","journal-title":"Phytochemistry"},{"key":"ref=31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0121099","volume":"10","author":"Tietjen I.","year":"2015","unstructured":"Tietjen I.; Ntie-Kang F.; Mwimanzi P.; Ongu\u00e9n\u00e9 P.A.; Scull M.A.; Idowu T.O.; Ogundaini A.O.; Meva\u2019a L.M.; Abegaz B.M.; Rice C.M.; Andrae-Marobela K.; Brockman M.A.; Brumme Z.L.; Fedida D.; Screening of the Pan-African natural product library identifies ixoratannin A-2 and boldine as novel HIV-1 inhibitors. PLoS One 2015,10(4)","journal-title":"PLoS One"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"90","DOI":"10.3329\/bjp.v3i2.838","volume":"3","author":"Saha M.R.","year":"2008","unstructured":"Saha M.R.; Alam M.A.; Akter R.; Jahangir R.; In-vitro free radical scavenging activity of Ixora coccinea L. Bangladesh J Pharmacol 2008,3,90-96","journal-title":"Bangladesh J Pharmacol"},{"key":"ref=33","first-page":"3","author":"Batugal P.A.","year":"2004","unstructured":"Batugal P.A.; Asia: The Framework And Project Work Plans, 1 2004,3-6","journal-title":"Asia: The Framework And Project Work Plans, 1"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/S0367-326X(99)00025-8","volume":"70","author":"Nayak B.S.","year":"1999","unstructured":"Nayak B.S.; Udupa A.L.; Udupa S.L.; Effect of Ixora coccinea flowers on dead space wound healing in rats. Fitoterapia 1999,70(3),233-236","journal-title":"Fitoterapia"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1016\/j.phytochem.2010.08.018","volume":"71","author":"Idowu T.O.","year":"2010","unstructured":"Idowu T.O.; Ogundaini A.O.; Salau A.O.; Obuotor E.M.; Bezabih M.; Abegaz B.M.; Doubly linked, A-type proanthocyanidin trimer and other constituents of Ixora coccinea leaves and their antioxidant and antibacterial properties. Phytochemistry 2010,71(17-18),2092-2098","journal-title":"Phytochemistry"},{"key":"ref=36","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1146\/annurev.bb.19.060190.001201","volume":"19","author":"Davies D.R.","year":"1990","unstructured":"Davies D.R.; The structure and function of the aspartic proteinases. Annu Rev Biophys Biophys Chem 1990,19(1),189-215","journal-title":"Annu Rev Biophys Biophys Chem"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1039\/b208248a","volume":"1","author":"Brik A.","year":"2003","unstructured":"Brik A.; Wong C.H.; HIV-1 protease: mechanism and drug discovery. Org Biomol Chem 2003,1(1),5-14","journal-title":"Org Biomol Chem"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"17203","DOI":"10.1074\/jbc.M114.571836","volume":"289","author":"Huang X.","year":"2014","unstructured":"Huang X.; Britto M.D.; Kear-Scott J.L.; Boone C.D.; Rocca J.R.; Simmerling C.; Mckenna R.; Bieri M.; Gooley P.R.; Dunn B.M.; Fanucci G.E.; The role of select subtype polymorphisms on HIV-1 protease conformational sampling and dynamics. J Biol Chem 2014,289(24),17203-17214","journal-title":"J Biol Chem"},{"key":"ref=39","doi-asserted-by":"publisher","first-page":"8356","DOI":"10.1073\/pnas.89.17.8356","volume":"89","author":"Curtis B.M.","year":"1992","unstructured":"Curtis B.M.; Scharnowske S.; Watson A.J.; Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120. Proc Natl Acad Sci USA 1992,89(17),8356-8360","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1038\/312763a0","volume":"312","author":"Dalgleish A.G.","year":"1984","unstructured":"Dalgleish A.G.; Beverley P.C.; Clapham P.R.; Crawford D.H.; Greaves M.F.; Weiss R.A.; The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984,312(5996),763-767","journal-title":"Nature"},{"key":"ref=41","first-page":"1","volume":"29","author":"Fiorentini S.","year":"2006","unstructured":"Fiorentini S.; Marini E.; Caracciolo S.; Caruso A.; Functions of the HIV-1 matrix protein p17. New Microbiol 2006,29(1),1-10","journal-title":"New Microbiol"},{"key":"ref=42","first-page":"183","volume":"4","author":"Klarmann G.J.","year":"2002","unstructured":"Klarmann G.J.; Hawkins M.E.; Le Grice S.F.; Uncovering the complexities of retroviral ribonuclease H reveals its potential as a therapeutic target. AIDS Rev 2002,4(4),183-194","journal-title":"AIDS Rev"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"2837","DOI":"10.2174\/092986710792065045","volume":"17","author":"Tramontano E.","year":"2010","unstructured":"Tramontano E.; Di Santo R.; HIV-1 RT-associated RNase H function inhibitors: recent advances in drug development. Curr Med Chem 2010,17(26),2837-2853","journal-title":"Curr Med Chem"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"8656","DOI":"10.1128\/JVI.00767-08","volume":"82","author":"Stanley B.J.","year":"2008","unstructured":"Stanley B.J.; Ehrlich E.S.; Short L.; Yu Y.; Xiao Z.; Yu X.F.; Xiong Y.; Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. J Virol 2008,82(17),8656-8663","journal-title":"J Virol"},{"key":"ref=45","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1186\/1742-4690-4-81","volume":"4","author":"Miller J.H.","year":"2007","unstructured":"Miller J.H.; Presnyak V.; Smith H.C.; The dimerization domain of HIV-1 viral infectivity factor Vif is required to block APOBEC3G incorporation with virions. Retrovirology 2007,4(1),81","journal-title":"Retrovirology"},{"key":"ref=46","doi-asserted-by":"crossref","first-page":"4322","DOI":"10.4049\/jimmunol.159.9.4322","volume":"159","author":"Moriuchi M.","year":"1997","unstructured":"Moriuchi M.; Moriuchi H.; Turner W.; Fauci A.S.; Cloning and analysis of the promoter region of CXCR4, a coreceptor for HIV-1 entry. J Immunol 1997,159(9),4322-4329","journal-title":"J Immunol"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0014-5793(98)00359-7","volume":"426","author":"Caruz A.","year":"1998","unstructured":"Caruz A.; Samsom M.; Alonso J.M.; Alcami J.; Baleux F.; Virelizier J.L.; Parmentier M.; Arenzana-Seisdedos F.; Genomic organization and promoter characterization of human CXCR4 gene. FEBS Lett 1998,426(2),271-278","journal-title":"FEBS Lett"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1182\/blood-2016-04-709519","volume":"128","author":"Pavlasova G.","year":"2016","unstructured":"Pavlasova G.; Borsky M.; Seda V.; Cerna K.; Osickova J.; Doubek M.; Mayer J.; Calogero R.; Trbusek M.; Pospisilova S.; Davids M.S.; Kipps T.J.; Brown J.R.; Mraz M.; Ibrutinib inhibits CD20 upregulation on CLL B cells mediated by the CXCR4\/SDF-1 axis. Blood 2016,128(12),1609-1613","journal-title":"Blood"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"15566","DOI":"10.1074\/jbc.M110.103408","volume":"285","author":"Saini V.","year":"2010","unstructured":"Saini V.; Marchese A.; Majetschak M.; CXC chemokine receptor 4 is a cell surface receptor for extracellular ubiquitin. J Biol Chem 2010,285(20),15566-15576","journal-title":"J Biol Chem"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.femsle.2004.09.040","volume":"241","author":"de Silva E.","year":"2004","unstructured":"de Silva E.; Stumpf M.P.; HIV and the CCR5-Delta32 resistance allele. FEMS Microbiol Lett 2004,241(1),1-12","journal-title":"FEMS Microbiol Lett"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1056\/NEJMoa0802905","volume":"360","author":"H\u00fctter G.","year":"2009","unstructured":"H\u00fctter G.; Nowak D.; Mossner M.; Ganepola S.; M\u00fcssig A.; Allers K.; Schneider T.; Hofmann J.; K\u00fccherer C.; Blau O.; Blau I.W.; Hofmann W.K.; Thiel E.; Long-term control of HIV by CCR5 Delta32\/Delta32 stem-cell transplantation. N Engl J Med 2009,360(7),692-698","journal-title":"N Engl J Med"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"2791","DOI":"10.1182\/blood-2010-09-309591","volume":"117","author":"Allers K.","year":"2011","unstructured":"Allers K.; H\u00fctter G.; Hofmann J.; Loddenkemper C.; Rieger K.; Thiel E.; Schneider T.; Evidence for the cure of HIV infection by CCR5\u039432\/\u039432 stem cell transplantation. Blood 2011,117(10),2791-2799","journal-title":"Blood"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/v6010001","volume":"6","author":"Zhen A.","year":"2013","unstructured":"Zhen A.; Kitchen S.; Stem-cell-based gene therapy for HIV infection. Viruses 2013,6(1),1-12","journal-title":"Viruses"},{"key":"ref=54","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1021\/ci500209e","volume":"54","author":"Santos-Martins D.","year":"2014","unstructured":"Santos-Martins D.; Forli S.; Ramos M.J.; Olson A.J.; AutoDock4(Zn): an improved AutoDock force field for small-molecule docking to zinc metalloproteins. J Chem Inf Model 2014,54(8),2371-2379","journal-title":"J Chem Inf Model"},{"key":"ref=55","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","volume":"31","author":"Trott O.","year":"2010","unstructured":"Trott O.; Olson A.J.; AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 2010,31(2),455-461","journal-title":"J Comput Chem"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/(SICI)1099-1352(199601)9:1<1:AID-JMR241>3.0.CO;2-6","volume":"9","author":"Goodsell D.S.","year":"1996","unstructured":"Goodsell D.S.; Morris G.M.; Olson A.J.; Automated docking of flexible ligands: applications of AutoDock. J Mol Recognit 1996,9(1),1-5","journal-title":"J Mol Recognit"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.drudis.2006.11.008","volume":"12","author":"Zimmermann G.R.","year":"2007","unstructured":"Zimmermann G.R.; Leh\u00e1r J.; Keith C.T.; Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov Today 2007,12(1-2),34-42","journal-title":"Drug Discov Today"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1146\/annurev-pharmtox-010611-134630","volume":"52","author":"Xie L.","year":"2012","unstructured":"Xie L.; Xie L.; Kinnings S.L.; Bourne P.E.; Novel computational approaches to polypharmacology as a means to define responses to individual drugs. Annu Rev Pharmacol Toxicol 2012,52,361-379","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"1871","DOI":"10.1016\/j.drudis.2014.08.006","volume":"19","author":"Koeberle A.","year":"2014","unstructured":"Koeberle A.; Werz O.; Multi-target approach for natural products in inflammation. Drug Discov Today 2014,19(12),1871-1882","journal-title":"Drug Discov Today"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/S1359-6446(04)03163-0","volume":"9","author":"Morphy R.","year":"2004","unstructured":"Morphy R.; Kay C.; Rankovic Z.; From magic bullets to designed multiple ligands. Drug Discov Today 2004,9(15),641-651","journal-title":"Drug Discov Today"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1038\/nbt1338","volume":"25","author":"Yildirim M.A.","year":"2007","unstructured":"Yildirim M.A.; Goh K.I.; Cusick M.E.; Barab\u00e1si A.L.; Vidal M.; Drug-target network. Nat Biotechnol 2007,25(10),1119-1126","journal-title":"Nat Biotechnol"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1038\/nrd1346","volume":"3","author":"Roth B.L.","year":"2004","unstructured":"Roth B.L.; Sheffler D.J.; Kroeze W.K.; Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug Discov 2004,3(4),353-359","journal-title":"Nat Rev Drug Discov"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/S0896-6273(00)81133-2","volume":"26","author":"Catterall W.A.","year":"2000","unstructured":"Catterall W.A.; From ionic currents to molecular mechanisms: the structure and function of voltage-gated sodium channels. Neuron 2000,26(1),13-25","journal-title":"Neuron"},{"key":"ref=64","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"Hopkins A.L.","year":"2008","unstructured":"Hopkins A.L.; Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 2008,4(11),682-690","journal-title":"Nat Chem Biol"},{"key":"ref=65","doi-asserted-by":"publisher","first-page":"959","DOI":"10.2174\/138955712802762356","volume":"12","author":"Talevi A.","year":"2012","unstructured":"Talevi A.; Bellera C.L.; Di Ianni M.; Gantner M.; Bruno-Blanch L.E.; Castro E.A.; CNS drug development - lost in translation? Mini Rev Med Chem 2012,12(10),959-970","journal-title":"Mini Rev Med Chem"},{"key":"ref=66","doi-asserted-by":"publisher","first-page":"2849","DOI":"10.1021\/acs.jmedchem.5b00497","volume":"59","author":"Zhan P.","year":"2016","unstructured":"Zhan P.; Pannecouque C.; De Clercq E.; Liu X.; Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends. J Med Chem 2016,59(7),2849-2878","journal-title":"J Med Chem"},{"key":"ref=67","doi-asserted-by":"publisher","first-page":"113","DOI":"10.3390\/ph7020113","volume":"7","author":"Zheng H.","year":"2014","unstructured":"Zheng H.; Fridkin M.; Youdim M.; From single target to multitarget\/network therapeutics in Alzheimer\u2019s therapy. Pharmaceuticals (Basel) 2014,7(2),113-135","journal-title":"Pharmaceuticals (Basel)"},{"key":"ref=68","first-page":"207","author":"Talevi A.","year":"2013","unstructured":"Talevi A.; Bruno-Blanch L.E.; \u201cOn the development of new antiepileptic drugs for the treatment of pharmacoresistant epilepsy: different approaches to different hypothesis,\u201d in Pharmacoresistance in Epilepsy: From Genes and Molecules to Promising Therapies 2013,207-224","journal-title":"\u201cOn the development of new antiepileptic drugs for the treatment of pharmacoresistant epilepsy: different approaches to different hypothesis,\u201d in Pharmacoresistance in Epilepsy: From Genes and Molecules to Promising Therapies"},{"key":"ref=69","doi-asserted-by":"publisher","first-page":"3126","DOI":"10.1021\/jm500131s","volume":"57","author":"Li K.","year":"2014","unstructured":"Li K.; Schurig-Briccio L.A.; Feng X.; Upadhyay A.; Pujari V.; Lechartier B.; Fontes F.L.; Yang H.; Rao G.; Zhu W.; Gulati A.; No J.H.; Cintra G.; Bogue S.; Liu Y.L.; Molohon K.; Orlean P.; Mitchell D.A.; Freitas-Junior L.; Ren F.; Sun H.; Jiang T.; Li Y.; Guo R.T.; Cole S.T.; Gennis R.B.; Crick D.C.; Oldfield E.; Multitarget drug discovery for tuberculosis and other infectious diseases. J Med Chem 2014,57(7),3126-3139","journal-title":"J Med Chem"}],"container-title":["Current Computer-Aided Drug Design"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/173163","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/173163\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/173163","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,20]],"date-time":"2024-07-20T15:36:24Z","timestamp":1721489784000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/173163\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,3]]},"references-count":69,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020,9,3]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573409915666190702111023","relation":{},"ISSN":["1573-4099"],"issn-type":[{"type":"print","value":"1573-4099"}],"subject":[],"published":{"date-parts":[[2020,9,3]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2019-01-09","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-04-25","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-05-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-09-03","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}